Athanassios Argiris, MD

Athanassios Argiris, MD, FACP

Contact Dr. Argiris

1025 Walnut Street
College Building, Suite 700
Philadelphia, PA 19107

(215) 955-8875
(215) 503-3408 fax

Most Recent Peer-reviewed Publications

  1. Induced Bias Due to Crossover Within Randomized Controlled Trials in Surgical Oncology: A Meta-regression Analysis of Minimally Invasive versus Open Surgery for the Treatment of Gastrointestinal Cancer
  2. Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3508)
  3. Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non–small cell lung cancer
  4. Evidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neck
  5. Increased PD-1+and TIM-3+TILs during cetuximab therapy inversely correlate with response in head and neck cancer patients
  6. Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer
  7. Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma
  8. Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer
  9. A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
  10. Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer
  11. Characterization of human papillomavirus antibodies in individuals with head and neck cancer
  12. Emerging aspects of nanotoxicology in health and disease: From agriculture and food sector to cancer therapeutics
  13. Postoperative treatment for head and neck cancer: The emerging role of EGFR-targeted therapy
  14. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors
  15. p53-Based strategy to reduce hematological toxicity of chemotherapy: A proof of principle study
  16. CTLA-4+ regulatory t cells increased in cetuximab-treated head and neck cancer patients suppress nk cell cytotoxicity and correlate with poor prognosis
  17. EGFR inhibition for recurrent or metastatic HNSCC
  18. Targeting angiogenesis in head and neck cancer
  19. Posttraumatic stress disorder symptoms in newly diagnosed patients with head and neck cancer and their partners
  20. Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck